Biotronik AG appears in FDA device records as the applicant for three PMA numbers covering coronary and peripheral stent systems. The filings describe a coronary drug-eluting stent and two self-expanding nitinol peripheral stent families, each carrying a distinct product code and generic device name. The records document original approvals and later manufacturing supplements, giving a dated view of how the applications have been maintained. The applicant address on these records is Ackerstrasse 6, Bülach, Switzerland; that is a filing address, and no headquarters location is established here. [1][2][3][4][5]
Coronary drug-eluting stent filing
PMA P170030 covers the ORSIRO Sirolimus Eluting Coronary Stent System under product code NIQ, generic name coronary drug-eluting stent. FDA's approval order is dated February 22, 2019, with a Federal Register notice date of February 25, 2019, and the application was received September 27, 2017. The approval statement describes the device as intended to improve coronary luminal diameter in patients with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in native coronary arteries. [4]
The Summary of Safety and Effectiveness Data for P170030 lists the applicant as BIOTRONIK, Inc., 6024 Jean Road, Lake Oswego, Oregon, and records the FDA notice of approval as February 22, 2019. The same document identifies the device trade name as the Orsiro Sirolimus Eluting Coronary Stent System and the product code as NIQ. [8][9]
A later 30-day notice, P170030/S066, was received August 25, 2026 and decided September 24, 2026 with decision code OK30. Its supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier, and the statement of the change cites solvent preparation and drug coating application. [1]
Peripheral nitinol stent filings
PMA P160025 covers the Astron Pulsar Stent System and Pulsar-18 Stent System under product code NIP, generic name stent for the superficial femoral artery. The approval decision is dated March 23, 2017, with a Federal Register notice date of March 29, 2017, and the application was received July 22, 2016. The approval statement describes use to improve luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions in the superficial femoral or proximal popliteal arteries. [5]
A supplement to that application, P160025/S026, covers the Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System. It was received August 5, 2026 and decided September 11, 2026 with decision code OK30, under the same process-change supplement reason, and its statement of change cites modifications to the gold-plating manufacturing equipment. [2]
PMA P140030 covers the Astron Peripheral Self-Expanding Nitinol Stent System under product code NIO, generic name iliac stent. Its supplement P140030/S025 was received August 5, 2026 and decided September 11, 2026 with decision code OK30, also a process change, with the same gold-plating equipment modification cited. The original P140030 approval record is not among the numbered sources, so its decision date is unknown here. [3]
How the records relate
The three PMA numbers sit with one applicant, Biotronik AG, and span coronary and peripheral indications with separate product codes. Two of the 2026 supplements share a decision date and an identical statement of change, while the coronary supplement addresses coating rather than plating equipment. FDA's PMA page for P170030 notes that the device has supplements and that the device description or indication may have changed, so the supplement records should be read alongside the original approval. [1][2][3][6]
The linked collection holds six records as of November 20, 2026: three original approvals and three 30-day notices, with decision counts of three OK30 and three APPR. The smaller record sample of five entries shows three OK30 and two APPR decisions. These counts describe the retrieved filings only and are not measures of total portfolio, sales or device safety. [1][2][3][4][5]







